In addition to ibrutinib, people with M-CLL, devoid of TP53 aberrations and in shape ample to tolerate FCR therapy, may still be good candidates with the latter, While using the gain currently being that this procedure could be concluded in six months although ibrutinib needs to be taken indefinitely. This option can be particularly worthwhile for